Victoria Morrison Knudsen1, Igor Kozak2. 1. Retina Associates of Utah, Murray, UT, USA. 2. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Abstract
PURPOSE: To evaluate success with intravitreal injection of ocriplasmin in releasing symptomatic vitreomacular traction (VMT). METHODS: A retrospective review of consecutive series of patients in a single vitreoretinal practice. Patients with symptomatic distortion and loss of vision secondary to VMT were included in the study. Patients received a single injection of ocriplasmin (JETREA®) and were followed-up after 1 month with optical coherence tomography. RESULTS: Eight patients (8 eyes) were included (2 males and 6 females) in the study. Five of 8 eyes (62.5%) experienced complete release of the VMT; one of 8 eyes (12.5%) had partial release of VMT and two of 8 eyes (25%) did not have release of VMT. The two patients with no release of their VMT had the same vision. Of the 5 patients with complete release of VMT, 3 patients had a one line worsening of their vision, 1 had a 4 line improvement of vision, and 1 stayed the same. The patient with only partial release of their VMT had a 1 line worsening of vision. CONCLUSIONS: Intravitreal ocriplasmin is a promising treatment option for vitreomacular traction syndrome in symptomatic patients.
PURPOSE: To evaluate success with intravitreal injection of ocriplasmin in releasing symptomatic vitreomacular traction (VMT). METHODS: A retrospective review of consecutive series of patients in a single vitreoretinal practice. Patients with symptomatic distortion and loss of vision secondary to VMT were included in the study. Patients received a single injection of ocriplasmin (JETREA®) and were followed-up after 1 month with optical coherence tomography. RESULTS: Eight patients (8 eyes) were included (2 males and 6 females) in the study. Five of 8 eyes (62.5%) experienced complete release of the VMT; one of 8 eyes (12.5%) had partial release of VMT and two of 8 eyes (25%) did not have release of VMT. The two patients with no release of their VMT had the same vision. Of the 5 patients with complete release of VMT, 3 patients had a one line worsening of their vision, 1 had a 4 line improvement of vision, and 1 stayed the same. The patient with only partial release of their VMT had a 1 line worsening of vision. CONCLUSIONS: Intravitreal ocriplasmin is a promising treatment option for vitreomacular traction syndrome in symptomatic patients.
Authors: Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller Journal: N Engl J Med Date: 2012-08-16 Impact factor: 91.245
Authors: Timothy L Jackson; Elena Nicod; Aris Angelis; Federico Grimaccia; Andrew T Prevost; Andrew R H Simpson; Panos Kanavos Journal: Retina Date: 2013 Nov-Dec Impact factor: 4.256